A study Bavituximab and Pembrolizumab for progressive recurrent/metastatic squamous cell carcinoma of the head and neck
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Bavituximab (Primary) ; Pembrolizumab
- Indications Head and neck cancer
- Focus Therapeutic Use
- 14 Jul 2017 According to a Peregrine Pharmaceuticals media release, this trial is expected to be initiated by the end of the calendar year 2017.
- 13 Mar 2017 This trial is on track to be initiated by mid-calendar 2017, according to a Peregrine Pharmaceuticals media release.
- 23 Sep 2016 New trial record